Oliver Lagore Vanvalin Investment Group Crispr Therapeutics Ag Transaction History
Oliver Lagore Vanvalin Investment Group
- $263 Million
- Q2 2025
A detailed history of Oliver Lagore Vanvalin Investment Group transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Oliver Lagore Vanvalin Investment Group holds 75 shares of CRSP stock, worth $4,230. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75
Previous 75
-0.0%
Holding current value
$4,230
Previous $2,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CRSP
# of Institutions
541Shares Held
68.6MCall Options Held
3.67MPut Options Held
2.25M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$574 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA5.59MShares$316 Million0.05% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.68MShares$208 Million0.11% of portfolio
-
State Street Corp Boston, MA3.27MShares$184 Million0.01% of portfolio
-
Ubs Group Ag2.84MShares$160 Million0.02% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.4B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....